雌激素与贝伐单抗等因子对SKBR-3乳腺癌细胞VEGF表达影响观察

Influence of estrogen,Bevacizumab on VEGF expression of SKBR-3 breast cancer cells

目的:观察不同浓度雌激素对SKBR-3乳腺癌细胞血管内皮生长因子(vascular endothelial growth factor,VEGF)表达的影响,并探讨不同浓度雌激素作用条件下,贝伐单抗(VEGF单抗)、曲妥珠单抗(HER-2单抗)、紫杉醇和胰岛素样生长因子1受体(insulin-like growth factor receptor,IGF-1R)抗体对SKBR-3乳腺癌细胞VEGF表达的影响。方法:利用RT-PCR方法检测SKBR-3乳腺癌细胞在不同浓度雌激素以及VEGF单抗(0.5μg/mL)、HER-2单抗(0.04μg/mL)、紫杉醇(1.5μg/mL)和IGF-1R抗体(2.5μg/mL)作用下,SKBR-3乳腺癌细胞VEGF的表达状况,利用ELISA方法检测培养液上清中VEGF蛋白浓度。结果:1)无雌激素组SKBR-3乳腺癌细胞VEGF表达为1.061 8±0.008 5(VEGF/GAPDH,下同),低浓度雌激素(0.05μg/mL)组为1.004 7±0.006 1,差异有统计学意义,P=0.002,高浓度雌激素(0.2μg/mL)组为1.086 8±0.013 5,差异有统计学意义,P<0.001。2)用与不用紫杉醇SKBR-3乳腺癌细胞VEGF表达分别为1.049 6±0.028 8和1.061 8±0.008 5,F=0.058;用与不用IGF-1R单抗为1.088 4±0.003 6和1.061 8±0.008 5,F=0.073;用与不用HER-2单抗分别为0.988 7±0.003 7和1.061 8±0.008 5,F=0.075;同时,在应用紫杉醇、IGF-1R单抗、HER-2单抗基础上加用雌激素VEGF表达不受影响。3)用与不用VEGF单抗SKBR-3乳腺癌细胞VEGF表达分别为1.005 7±0.004 3、1.061 8±0.008 5,差异有统计学意义,F=0.132,P=0.04;但雌激素与VEGF单抗对VEGF表达影响没有协同作用。结论:不同雌激素浓度对SKBR-3乳腺癌细胞VEGF表达影响明显;紫杉醇、IGF-1R单抗和HER-2单抗不影响SKBR-3乳腺癌细胞VEGF表达,与雌激素也无协同作用;VEGF单抗升高VEGF表达,也与雌激素没有协同作用。

OBJECTIVE： To investigate expression of VEGF of SKBR-3 breast cancer cells in different estrogen and to investigate the expression of VEGF after Bevacizumab,Trastuzumab,Taxol and IGF-1R antibody treatment in different estrogen. METHODS： We examined VEGF-expression of the SKBR-3 breast cancer cells aftel： different cancentration of estrogen, Arastin, H erceptin, Taxoland IGF-1R antibody with RT-PCR. VEGF protein in supernate was detected by ELE- SA. RESULTS： The expression of VEGF in conto group was 1. 061 80. 008 5 （VEGF/GAPDH） ,the expression of VEGF in low concentration group（50 μg/L） was 1. 004 7 ± 0. 006 1 （P= 0. 002）, the expression of VEGF in high concentration group （0.2 μg/mL） was 1. 086 8-1-0. 013 5（P〈0. 001）. The expression of VEGF were 1. 049 6±0. 028 8 and 1. 061 8±0. 008 5 in Taxol group and contral group（F= 0. 058） ,the expression of VEGF were 1. 088 4 ± 0. 003 6,1. 061 8 ± 0. 008 5 in antibody of IGF-1R group and contral group（ F= 0. 073）, the expression of VEGF were 0. 988 7 ± 0. 003 7,1. 061 8 ± 0. 008 5 in Trastuzumab group and contral group（F=0. 075）. There were no change of VEGF expression in Taxol group, antibody of IGF1R group and Trastuzumab group with estrogen. The expression of VEGF were 1. 005 7±0. 004 3 and 1. 061 8±0. 008 5 in Bevacizumab group and eontral group（F=0. 132, P= 0. 004） and estrogen had no influence on the action. CONCLUSIONS： The influence of different estrogen on VEGF expression in SKBR-3 breast cancer cells is remarkable. Taxol, antibody of IGF-1R and Trastuzumab do not change the expression of VEGF in SKBR-3 breast cancer cells and estrogen had no influence to this action. Bevacizumab increases the expression of VEGF and estrogen do not change the action.